Characterization of the Clinical-epidemiological Profile of Patients With Spinal Muscular Atrophy (SMA) 5q Types II and III in Follow-up in the Brazilian Unified Public Health System: A Cross-sectional Observational Study (Registry)
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
Most Recent Events
- 23 Apr 2021 Status changed from recruiting to completed.
- 11 Jan 2021 Planned End Date changed from 31 Dec 2020 to 30 Apr 2021.
- 11 Jan 2021 Planned primary completion date changed from 31 Dec 2020 to 30 Apr 2021.